Abstract:BACKGROUND: Hepatic encephalopathy (HE) can be considered a result of dysregulated gut-liver-brain axis function, where cognitive impairment can be reversed or prevented by the beneficial effects induced by "gut-centric" therapies, such as the administration of nonabsorbable disaccharides, nonabsorbable antibiotics, probiotics and prebiotics.AIM: To assess the short-term efficacy and safety of the probiotic Escherichia coli Nissle (EcN) 1917 strain compared to lactulose and rifaximin in patients with minimal/mild HE.METHODS: From January 2017 to March 2020, a total of 45 patients with HE were enrolled in this prospective, single-centre, open-label, randomized study. Participants were randomly assigned at a ratio of 1:1:1 to one of the treatment groups: The EcN group (n = 15), lactulose group (n = 15) or rifaximin group (n = 15) for a 1 mo intervention period. The main primary outcomes of the study were changes in serum ammonia and Stroop test score. The secondary outcomes were markers of a chronic systemic inflammatory response (ІL-6, ІL-8, and IFN-γ) and bacteriology of the stool flora evaluated by specialized nonculture techniques after a 1 mo intervention period.RESULTS: Patients who were given rifaximin or EcN showed a more significant reduction in serum ammonia and normalization of Bifidobacteria and Lactobacilli abundance compared to the lactulose group. However, the most pronounced restoration of the symbiotic microflora was associated with EcN administration and characterized by the absence of E. coli with altered properties and pathogenic enterobacteria in patient faeces. In the primary outcome analysis, improvements in the Stroop test parameters in all intervention groups were observed. Moreover, EcN-treated patients performed 15% faster on the Stroop test than the lactulose group patients (P = 0.017). Both EcN and rifaximin produced similar significant reductions in the proinflammatory cytokines INF-γ, IL-6 and IL-8. EcN was more efficient than lactulose in reducing proinflammatory cytokine levels.CONCLUSION: The use of the probiotic EcN strain was safe and quite efficient for HE treatment. The probiotic reduced the ammonia content and the level of serum proinflammatory cytokines, normalized the gut microbiota composition and improved the cognitive function of patients with HE. The application of the EcN strain was more effective than lactulose treatment.

The effect of rifaximin and lactulose treatments to chronic hepatic encephalopathy rats: An [18F]PBR146 in-vivo neuroinflammation imaging study

The Neuroinflammation Imaging of Bifidobacterium and Fecal Microbiota Transplantation: Therapeutic Effects Evaluation in Chronic Hepatic Encephalopathy Rats by [18F]PBR146 In-Vivo Imaging

[18F]PBR146 and [18F]DPA-714 in vivo Imaging of Neuroinflammation in Chronic Hepatic Encephalopathy Rats

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome

The effect of histone deacetylase inhibitor ACY1215 on the inflammatory response in mice with acute liver failure

Intervention Effect of Likailing Decoction on Secondary Intestinal Endotoxemia after Intracerebral Hemorrhage in Rats

F-18- Dpa-714 Pet Imaging For Detecting Neuroinflammation In Rats With Chronic Hepatic Encephalopathy

Neuroinflammation in Acute Hepatic Encephalopathy Rats: Imaging and Therapeutic Effectiveness Evaluation Using 11C-PK11195 and 18F-DPA-714 Micro-Positron Emission Tomography.

<i>Bifidobacterium longum</i> R0175 Protects Rats against D-Galactosamine-Induced Acute Liver Failure

Lactobacillus Reuteri DSM 17938 Alleviates D-Galactosamine-induced Liver Failure in Rats.

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota

Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan

Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment

Dynamic Variability of Intestinal Flora and Endotoxin in Rat with Fulminate Hepatic Failure

Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids

Rifaximin protects SH‐SY5Y neuronal cells from iron overload‐induced cytotoxicity via inhibiting STAT3/NF‐κB signaling

S1795 Rifaxmin and Lactulose vs Rifaximin and Miralax Therapy in Preventing Hepatic Encephalopathy: A Comparitive Analysis

Study on the molecular mechanisms of rifaximin in the treatment of non‐alcoholic steatohepatitis based on the Helicobacter ‐DCA‐Fxr‐Hnf1α signalling pathway

Intestinal Dysbacteriosis Contributes to Persistent Cognitive Impairment after Resolution of Acute Liver Failure

Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial

Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis